« Zurück
Home /
Ravoxertinib

Ravoxertinib

ArtNr	HY-15947-50mg
Hersteller	MedChem Express
CAS-Nr.	1453848-26-4
Menge	50 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Colorectal Cancer
Typ	Inhibitors
Clon	N/A
Specific against	other
Purity	99.75
Formula	C21H18ClFN6O2
Citations	ACS Comb Sci. 2019 Dec 9;21(12):805-816.<br>Am J Cancer Res. 2020 Nov 1;10(11):3622-3643.<br>Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592.<br>Biochem Biophys Res Commun. 2021 Mar 26;554:63-70.<br>Cancer Cell. 2023 Jul 10;41(7):1345-1362.e9.<br>Cancer. 2020 Mar 15;126(6):1339-1350.<br>Cancers (Basel). 2022 Mar 19;14(6):1575.<br>Cancers (Basel). 2022 May 19;14(10):2493.<br>Cell Death Dis. 2021 Dec 1;12(12):1123.<br>Cell Mol Immunol. 2023 Jan 5.<br>Cell Rep. 2023 Sep 1;42(9):113048.<br>Cell Signal. 2023 Jan 20;110607.<br>Cell. 2018 Sep 20;175(1):186-199.e19.<br>Clin Transl Med. 2023 Aug;13(8):e1381.<br>Diabetes. 2021 Jun 21;db200719.<br>Environ Pollut. 2021 Jan 1;268(Pt B):115748.<br>Exp Mol Pathol. 2021 Feb;118:104587.<br>Gastric Cancer. 2023 Feb 22.<br>Harvard Medical School LINCS LIBRARY<br>Indian J Pharm Sci. 2022.<br>Int J Med Sci. 2022 Jan 1;19(1):195-204.<br>J Cell Biochem. 2020 Mar;121(3):2343-2353.<br>J Cell Mol Med. 2020 Sep;24(17):10151-10165.<br>J Exp Clin Cancer Res. 2023 Jul 13;42(1):166.<br>J Pharmacol Exp Ther. 2020 Jul;374(1):104-112.<br>Methods Mol Biol. 2018;1711:351-398.<br>Mol Oncol. 2020 Nov;14(11):2894-2919.<br>Nat Commun. 2023 Sep 30;14(1):6117.<br>Nat Metab. 2022 Mar;4(3):374-388.<br>Neural Regen Res. 2023.<br>Oncogene. 2021 Jul;40(30):4884-4893.<br>Proteomics. 2023 May 4;e2300041.<br>Redox Biol. 2023 Jul 24, 102825.<br>Reprod Sci. 2020 Feb;27(2):704-712.<br>Sci Transl Med. 2021 Jan 27;13(578):eaba7308.<br>Toxicol In Vitro. 2020 Jun;65:104777.<br>Universität Würzburg. Graduate School of Life Sciences. 2021 Jan.<br>Université de Lausanne. 2024 Feb 7.<br>Zool Res. 2022 Jul 18;43(4):537-551.<br>ACS Omega. 2023 May 23.<br>Nucleic Acids Res. 2022 Apr 8;50(6):3096-3114.<br>Pathol Res Pract. December 2021, 153682.<br>[1]MICHAEL LAI. Opportunity for Pharmaceutical Intervention in Lung Cancer: Selective Inhibition of JAK1/2 to Eliminate EMT-Derived Mesenchymal Cells.<br>[2]Blake JF, et al. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Developme<br>[3]Kirk Robarge, et al. Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development. Proceedings: AACR Annual Meeting 2014; April 5-9, 2014.
Smiles	O=C1C=C(C2=NC(NC3=CC=NN3C)=NC=C2)C=CN1[C@@H](C4=CC=C(Cl)C(F)=C4)CO
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	GDC-0994
Lieferbar
Product Description	Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with an IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	440.86
Clinical_Information	Phase 1
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 35 mg/mL
Manufacturers Target	ERK
Isoform	ERK1; ERK2
Pathway	MAPK/ERK Pathway; Stem Cell/Wnt

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-15947-50mg-safety-datasheet.pdf